# A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants

> **NCT04277624** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** fezolinetant - test formulation
- **DRUG:** fezolinetant - reference formulation

## Key facts

- **NCT ID:** NCT04277624
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-20
- **Primary completion:** 2021-02-21
- **Final completion:** 2021-02-26
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04277624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04277624, "A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04277624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*